{"id":24996,"date":"2023-05-03T15:22:46","date_gmt":"2023-05-03T13:22:46","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=24996"},"modified":"2023-05-03T15:22:46","modified_gmt":"2023-05-03T13:22:46","slug":"ligoniu-kasos-onkologiniams-vaistams-kompensuoti-trigubai-daugiau-lesu","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/en\/2023\/05\/03\/ligoniu-kasos-onkologiniams-vaistams-kompensuoti-trigubai-daugiau-lesu\/","title":{"rendered":"Ligoni\u0173 kasos: onkologiniams vaistams kompensuoti \u2013 trigubai daugiau l\u0117\u0161\u0173"},"content":{"rendered":"<p><strong>Per pastaruosius septynerius metus Privalomojo sveikatos draudimo fondo i\u0161laidos prie\u0161navikiniams vaistams kompensuoti Lietuvos gyventojams padid\u0117jo tris kartus, rodo Valstybin\u0117s ligoni\u0173 kasos prie Sveikatos apsaugos ministerijos (VLK) atlikta analiz\u0117.\u00a0<\/strong><\/p>\n<p>\u201e2016 metais prie\u0161navikiniams vaistams kompensuoti prireik\u0117 64 mln. eur\u0173 Privalomojo sveikatos draudimo fondo l\u0117\u0161\u0173. Kasmet finansavimas onkologiniams vaistams did\u0117jo ma\u017edaug po 20 proc. ir pernai \u0161ios i\u0161laidos i\u0161augo trigubai \u2013 iki 193 mln. eur\u0173. Jokia kita vaist\u0173 grup\u0117 per kelet\u0105 met\u0173 nepatyr\u0117 tokio spartaus augimo kaip \u0161i\u201c, \u2013 pastebi VLK Vaist\u0173 kompensavimo skyriaus ved\u0117jas Evaldas Stropus.<\/p>\n<p>Neabejojama, kad tok\u012f reik\u0161ming\u0105 \u0161uol\u012f l\u0117m\u0117 ne tik per 2016\u20132022 m. laikotarp\u012f gerokai i\u0161aug\u0119s onkologin\u0117mis ligomis sergan\u010di\u0173 pacient\u0173 skai\u010dius, bet ir daugelio nauj\u0173, itin brangi\u0173 vaist\u0173 \u012ftraukimas \u012f kompensavimo sistem\u0105.<\/p>\n<p>\u201e2016 metais kompensuojam\u0173j\u0173 vaist\u0173 s\u0105ra\u0161e buvo \u012fra\u0161yti 85 vaistai onkologin\u0117ms ligoms gydyti, \u00a0o praeitais metais ligoni\u0173 kasos kompensavo jau 130 skirting\u0173 prie\u0161navikini\u0173 vaist\u0173\u201c, \u2013 sako E. Stropus.<\/p>\n<p>Analiz\u0117s duomenimis, daugiausiai Privalomojo sveikatos draudimo fondo l\u0117\u0161\u0173 pernai pareikalavo bronch\u0173 ir plau\u010di\u0173 piktybini\u0173 navik\u0173 gydymas kompensuojamaisiais vaistais. Tam prireik\u0117 daugiau nei 27 mln. eur\u0173. Dar beveik 21 mln. eur\u0173 praeitais metais buvo skirta vaistams nuo piktybin\u0117s melanomos kompensuoti, o per 17 mln. eur\u0173 \u2013 vaistams kr\u016bties v\u0117\u017eiui gydyti. Taip pat daugiau nei 15 mln. eur\u0173 skirta limfoidine leukemija ir arti 14 mln. eur\u0173 inkst\u0173 v\u0117\u017eiu sergan\u010di\u0173 pacient\u0173 vaistams kompensuoti.<\/p>\n<p>VLK specialist\u0173 atlikta analiz\u0117 taip pat atskleid\u0117, kad 2022 m. kompensuojamuosius prie\u0161navikinius vaistus Lietuvoje vartojo beveik 45 t\u016bkst. \u017emoni\u0173, t. y. net 11 t\u016bkst. pacient\u0173 daugiau nei 2016-aisiais. Tai rodo, kad per pastaruosius metus \u017eymiai pager\u0117jo onkologini\u0173 lig\u0173 diagnostika, o brangi\u0173 inovatyvi\u0173 prie\u0161navikini\u0173 vaist\u0173 \u012ftraukimas \u012f kompensavimo sistem\u0105 pasiteisino ir galimai l\u0117m\u0117 ilgesn\u012f onkologin\u0117mis ligomis sergan\u010di\u0173 pacient\u0173 i\u0161gyvenamum\u0105.<\/p>\n<p><img data-recalc-dims=\"1\" decoding=\"async\" src=\"https:\/\/i0.wp.com\/ligoniukasa.lrv.lt\/uploads\/ligoniukasa\/documents\/images\/PSDF%20i%C5%A1laid%C5%B3%20kompensuojamiesiems%20prie%C5%A1navikiniams%20vaistams%20ir%20pacient%C5%B3%20skai%C4%8Diaus%20dinamika%281%29.png?w=1200&#038;ssl=1\" alt=\"\" \/><\/p>\n<p><em>(Piktochart nuotr.)<\/em><\/p>\n<p><strong>Ligoni\u0173 kasos kvie\u010dia:<\/strong><\/p>\n<ul>\n<li><em>Skaityti svarbiausias naujienas Facebook:\u00a0<a href=\"https:\/\/goo.gl\/ML8SqJ\" target=\"_blank\" rel=\"noopener\">https:\/\/goo.gl\/ML8SqJ<\/a><\/em><\/li>\n<li><em>Pamatyti naujausias nuotraukas \ud83d\ude09 Instagram:\u00a0<a href=\"https:\/\/goo.gl\/tXvpXr\" target=\"_blank\" rel=\"noopener\">https:\/\/goo.gl\/tXvpXr<\/a><\/em><\/li>\n<li><em>\u017di\u016br\u0117ti i\u0161samius ir linksmus vaizdo \u012fra\u0161us Youtube:\u00a0<a href=\"https:\/\/goo.gl\/BPBep2\" target=\"_blank\" rel=\"noopener\">https:\/\/goo.gl\/BPBep2<\/a><\/em><\/li>\n<li><em>Sekti i\u0161skirtinius infografikus ir ne tik Flickr:\u00a0<a href=\"https:\/\/goo.gl\/bGtZg2\" target=\"_blank\" rel=\"noopener\">https:\/\/goo.gl\/bGtZg2<\/a><\/em><\/li>\n<li><em>R\u016bpimus klausimus galima pateikti\u00a0<a href=\"mailto:patlk@vlk.lt\">info@vlk.lt<\/a>\u00a0arba (8 5) 232 2222.<\/em><\/li>\n<\/ul>\n<p>VLK informacija<\/p>","protected":false},"excerpt":{"rendered":"<p>Per pastaruosius septynerius metus Privalomojo sveikatos draudimo fondo i\u0161laidos prie\u0161navikiniams vaistams kompensuoti Lietuvos gyventojams padid\u0117jo tris kartus, rodo Valstybin\u0117s ligoni\u0173 kasos prie Sveikatos apsaugos ministerijos (VLK) atlikta analiz\u0117.\u00a0 \u201e2016 metais prie\u0161navikiniams vaistams kompensuoti prireik\u0117 64 mln. eur\u0173 Privalomojo sveikatos draudimo fondo l\u0117\u0161\u0173. Kasmet finansavimas onkologiniams vaistams did\u0117jo ma\u017edaug po 20 proc. ir pernai \u0161ios i\u0161laidos&hellip;<\/p>","protected":false},"author":3,"featured_media":24997,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[6],"tags":[],"class_list":["post-24996","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-naujienos","category-6","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-6va","jetpack_featured_media_url":"https:\/\/vilkaviskiovsb.lt\/wp-content\/uploads\/2023\/05\/1899_051faff99580731bf9480ca873ee9929.jpg","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/24996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/comments?post=24996"}],"version-history":[{"count":1,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/24996\/revisions"}],"predecessor-version":[{"id":24998,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/24996\/revisions\/24998"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media\/24997"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media?parent=24996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/categories?post=24996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/tags?post=24996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}